5 Key Takeaways

• 1

  GSK's RSV vaccine Arexvy has been accepted for review by China's Center for Drug Evaluation for adults aged 60 and older.

• 2

  If approved, Arexvy would be the first RSV vaccine available in China for older adults, addressing significant health risks.

• 3

  RSV affects over six million adults aged 60 and older in China annually, leading to more than 350,000 hospitalizations.

• 4

  The regulatory submission is backed by positive phase 3 trial results, meeting all primary endpoints with an acceptable safety profile.

• 5

  Arexvy is already approved in over 65 countries for adults aged 60 and older, and in over 60 countries for those aged 50-59 with risk factors.